Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 4

Conditions

Solid Tumors 4Solid Tumor 1Lymphoid Malignancy 1

Interventions

Paclitaxel 15atezolizumab 11Gemcitabine 11Carboplatin 9pembrolizumab 8Docetaxel 8Bevacizumab 8Irinotecan 7Injections 6Cetuximab 6Capecitabine 6Sunitinib 5Leucovorin 5Fluorouracil 5Cyclophosphamide 5tocilizumab 4pazopanib 4olaparib 4navitoclax 4liposomal doxorubicin 4Topotecan 4Oxaliplatin 4Nivolumab 4Erlotinib Hydrochloride 4temsirolimus 3spartalizumab 3lenvatinib 3fludarabine 3cobimetinib 3Cisplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Solid Tumors × navitoclax × Other solid neoplasm × Clear all
NCT00878449 2018-06-06

A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer

AbbVie

Phase 1 Completed
12 enrolled
Other solid neoplasm

Solid Tumors

NCT00887757 2017-11-21

Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors

AbbVie

Phase 1 Completed
46 enrolled
Other solid neoplasm

Solid Tumors

NCT00891605 2017-11-21

Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors

AbbVie

Phase 1 Completed
19 enrolled
Other solid neoplasm

Solid Tumors

NCT01009073 2017-11-20

A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects

AbbVie

Phase 1 Completed
51 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡